{"product_id":"handbook-of-hypertension-paperback-softback-9781405182508","title":"Handbook of Hypertension (Paperback \/ softback) 9781405182508","description":"\u003cfont face=\"Georgia\"\u003e\r\n\u003cp\u003e\u003cfont size=\"6\"\u003eHandbook of Hypertension\u003c\/font\u003e\u003cbr\u003e\r\n\r\n\r\n\r\n\r\n\r\n\u003c\/p\u003e\n\u003cp\u003e\u003cfont size=\"4\"\u003eMark Houston (Author)\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e9781405182508, Wiley\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003ePaperback \/ softback, published 9 April 2009\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e412 pages\u003cbr\u003e21.6 x 14.1 x 2.4 cm, 0.526 kg\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\r\n\r\n\u003cp align=\"justify\"\u003e\u003cstrong\u003e\u003cfont size=\"3\"\u003eWhen treating hypertension, physicians now have a huge range of drugs from which to choose in formulating a management strategy. This accessible guide helps the busy clinician access specific information on available drugs as components of an integrated care plan.  \u003cp\u003eThe \u003ci\u003eHandbook of Hypertension\u003c\/i\u003e is a comprehensive review of the evidence base for hypertension and associated disease, providing tables, figures, charts, and summaries of principal findings from clinical studies on hypertension – putting vital information within reach of the busy practitioner.\u003c\/p\u003e \u003cp\u003eContaining the most recent guidelines for global cardiovascular risk analysis and evidence-based reviews on important new advances and recent trials, consulting the \u003ci\u003eHandbook of Hypertension\u003c\/i\u003e will save precious time and improve patient care.\u003c\/p\u003e\u003c\/font\u003e\u003c\/strong\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eProvisional Table of Contents.  \u003cp\u003e\u003cb\u003eAbbreviations\u003c\/b\u003e.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eGeneral Introduction\u003c\/b\u003e .\u003c\/p\u003e \u003cp\u003e\u003cb\u003eIntroduction\u003c\/b\u003e.\u003c\/p\u003e \u003cp\u003eHypertension Syndrome.\u003c\/p\u003e \u003cp\u003eVascular Biology.\u003c\/p\u003e \u003cp\u003eFunctional Endothelium.\u003c\/p\u003e \u003cp\u003eEndothelial Dysfunction.\u003c\/p\u003e \u003cp\u003eNew Treatment Approach.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eHypothesis: Essential Hypertension and End-Organ Damage\u003c\/b\u003e.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eHypertension Classification and Guidelines Wordwide\u003c\/b\u003e.\u003c\/p\u003e \u003cp\u003eHypertension in the US.\u003c\/p\u003e \u003cp\u003eJNC-7.\u003c\/p\u003e \u003cp\u003eNHANES III and IV.\u003c\/p\u003e \u003cp\u003eCHS.\u003c\/p\u003e \u003cp\u003eESH-ESC.\u003c\/p\u003e \u003cp\u003eISHIB.\u003c\/p\u003e \u003cp\u003eAHA.\u003c\/p\u003e \u003cp\u003eBHS\/NICE(RCP).\u003c\/p\u003e \u003cp\u003eJBS 2.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eGlobal Cardiovascular Risk Calculation.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSecondary Hypertension.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eMeasurement of Blood Pressure\u003c\/b\u003e.\u003c\/p\u003e \u003cp\u003eIndirect measurement of blood pressure.\u003c\/p\u003e \u003cp\u003eKorotkoff Sounds.\u003c\/p\u003e \u003cp\u003eCommon Mistakes in Blood Pressure Measurement.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eHypertension-Atherosclerotic Syndrome.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eNormotensive Hypertension.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePre-hypertension.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eNonpharmacologic Treatment of Hypertension.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eNutrition.\u003c\/p\u003e \u003cp\u003eNutraceuticals, Vitamins, Minerals and Antioxidants.\u003c\/p\u003e \u003cp\u003eDASH I and II Trials.\u003c\/p\u003e \u003cp\u003eSpecific Recommendations.\u003c\/p\u003e \u003cp\u003eObesity.\u003c\/p\u003e \u003cp\u003eExercise.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eApproaches to Selection of Antihypertensive Therapy\u003c\/b\u003e.\u003c\/p\u003e \u003cp\u003eStepped Care.\u003c\/p\u003e \u003cp\u003eDemographics.\u003c\/p\u003e \u003cp\u003eSubsets of Hypertension.\u003c\/p\u003e \u003cp\u003eRenin Profiling: The Laragh Method.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eHemodynamics in Hypertension.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eHemodynamics: Logical and Preferred Method to Reduce Blood Pressure.\u003c\/p\u003e \u003cp\u003eHemodynamic Effects of Antihypertensive Drugs.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eHypertension-Related End-Organ Damage.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eLife Expectancy and Blood Pressure.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSystolic, Diastolic and Pulse Pressure Concepts.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eIsolated Systolic Hypertension.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eClinical Hypertension Trials and Antihypertensive\u003c\/b\u003e .\u003c\/p\u003e \u003cp\u003e\u003cb\u003eDrug\u003c\/b\u003e \u003cb\u003eTherapy\u003c\/b\u003e .\u003c\/p\u003e \u003cp\u003eCompleted Trials and Trials in Progress.\u003c\/p\u003e \u003cp\u003eDiuretic and Beta-Blocker Trials.\u003c\/p\u003e \u003cp\u003eSummary of Clinical Trials with Diuretics.\u003c\/p\u003e \u003cp\u003eSummary of Clinical Trials with Beta-Blockers.\u003c\/p\u003e \u003cp\u003eMeta-Analysis of Various Clinical Trials.\u003c\/p\u003e \u003cp\u003eComparisons of ACE-Inhibitor therapy with Placebo.\u003c\/p\u003e \u003cp\u003eComparisons of Calcium-antagonist therapy with Placebo.\u003c\/p\u003e \u003cp\u003eComparisons of More Intensive Blood Pressure Lowering Strategies with Less.\u003c\/p\u003e \u003cp\u003eIntensive Strategies.\u003c\/p\u003e \u003cp\u003eComparisons of Ace-Inhibitor based Therapy with Diuretic-based or Beta-Blocker Therapy.\u003c\/p\u003e \u003cp\u003eComparisons of Calcium-antagonist-based Therapy with Diuretic or Beta-BlockerTherapy.\u003c\/p\u003e \u003cp\u003eComparisons of Ace-Inhibitor Therapy with Calcium-antagonist Therapy.\u003c\/p\u003e \u003cp\u003eSummary of Clinical Trials in Hypertension and Clinical Outcomes.\u003c\/p\u003e \u003cp\u003eHealth Outcomes Meta-Analysis.\u003c\/p\u003e \u003cp\u003eComparing the CCBs to other Antihypertensive Therapy.\u003c\/p\u003e \u003cp\u003eALLHAT Trial.\u003c\/p\u003e \u003cp\u003eALLHAT: Conclusions.\u003c\/p\u003e \u003cp\u003eASCOT Trial.\u003c\/p\u003e \u003cp\u003eSummary of Published Trials Involving CCBs.\u003c\/p\u003e \u003cp\u003eAngiotensin Converting Enzyme Inhibitors (ACEI) Trials.\u003c\/p\u003e \u003cp\u003eSummary of ACEI Trials.\u003c\/p\u003e \u003cp\u003eAngiotensin Receptor Blockers (ARBs) Trials.\u003c\/p\u003e \u003cp\u003eARBs Trials Summary.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eCoronary Heart Disease Risk Factor and Effects of Anti-hypertensive Drug Therapy\u003c\/b\u003e.\u003c\/p\u003e \u003cp\u003eCoronary Heart Disease: Risk Factors.\u003c\/p\u003e \u003cp\u003eCoronary Heart Disease Risk Factors: More potential risk factors.\u003c\/p\u003e \u003cp\u003eInfluence of Diuretic and Beta-Blocker Therapy on CHD Risk Factors.\u003c\/p\u003e \u003cp\u003eAntihypertensive Drugs and Serum Lipids.\u003c\/p\u003e \u003cp\u003eSummary of Serum Lipids and Antihypertensive Therapy with Diuretics and.\u003c\/p\u003e \u003cp\u003eBeta Blockers.\u003c\/p\u003e \u003cp\u003eEffects of Antihypertensive Drugs on Coronary Heart Disease Risk Factors.\u003c\/p\u003e \u003cp\u003eAntihypertensive Drugs and Coronary Heart Disease Risk Factors: Summary.\u003c\/p\u003e \u003cp\u003eCalcium Channel Blockers and Atherosclerosis (CHD Reduction Trials).\u003c\/p\u003e \u003cp\u003e\u003cb\u003eHypertension and Renal Disease\u003c\/b\u003e.\u003c\/p\u003e \u003cp\u003eClassification of Chronic Kidney Disease.\u003c\/p\u003e \u003cp\u003eHypertension and Renal Damage.\u003c\/p\u003e \u003cp\u003eHypertension-Related Renal Damage:.\u003c\/p\u003e \u003cp\u003ePostulated Mechanisms.\u003c\/p\u003e \u003cp\u003eIs Thiazide Diuretic-Based Antihypertensive Therapy Associated with Increased.\u003c\/p\u003e \u003cp\u003eRisk of Renal Injury.\u003c\/p\u003e \u003cp\u003eMajor Clinical Trials Showing Renoprotection.\u003c\/p\u003e \u003cp\u003eEffects of Antihypertensive Drugs on Renal Function.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eHypertension and Diabetes Mellitus\u003c\/b\u003e.\u003c\/p\u003e \u003cp\u003eHypertensive Diabetics: Mortality, Coronary Heart Disease and Antihypertensive.\u003c\/p\u003e \u003cp\u003eTherapy.\u003c\/p\u003e \u003cp\u003eBP Level Effects on Type II-DM Nephropathy.\u003c\/p\u003e \u003cp\u003eRENAAL TRIAL.\u003c\/p\u003e \u003cp\u003eDiabetes Mellitus and Hypertension Summary.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSelection of Therapy Based on Subsets of Hypertension.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eDemographics and Antihypertensive Drugs.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eResistant Hypertension.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eIsolated Systolic Hypertension in the Elderly.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eHypertensive Urgencies and Emergencies.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eTreatment; General Principles.\u003c\/p\u003e \u003cp\u003eTreatment; Choice of Drug.\u003c\/p\u003e \u003cp\u003eTreatment of Specific Hypertensive Disorders.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eHypertension in Pregnancy.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eGeneral Review of Antihypertensive Drug Therapy.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eQuality of Life and Antihypertensive Therapy (Selected Trials).\u003c\/p\u003e \u003cp\u003eAntihypertensive Drug Compliance.\u003c\/p\u003e \u003cp\u003eTotal Cost of Antihypertensive Therapy.\u003c\/p\u003e \u003cp\u003eCharacteristics of the Ideal Antihypertensive Drug.\u003c\/p\u003e \u003cp\u003eCombination Antihypertensive Therapy: Selected Drugs.\u003c\/p\u003e \u003cp\u003eCombination Antihypertensive Therapy: Selected Drugs: Summary.\u003c\/p\u003e \u003cp\u003eAntihypertensive Therapy: Efficacy of Monotherapy.\u003c\/p\u003e \u003cp\u003eSelected Drug Interactions with Antihypertensive Therapy.\u003c\/p\u003e \u003cp\u003eMaximum Recommended Doses of Antihypertensive Drugs with Best Treatment Characteristics.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSpecific Review of all Antihypertensive Drug Classes\u003c\/b\u003e.\u003c\/p\u003e \u003cp\u003eDiuretics.\u003c\/p\u003e \u003cp\u003eDiuretics Highlights.\u003c\/p\u003e \u003cp\u003eCentral Alpha-Agonists.\u003c\/p\u003e \u003cp\u003eCentral Alpha-Agonists: Similarities.\u003c\/p\u003e \u003cp\u003eCentral Alpha-Agonists: Highlights.\u003c\/p\u003e \u003cp\u003eComparison of Commonly Used Oral Central Alpha-Agonists.\u003c\/p\u003e \u003cp\u003ePostganglionic Neuron Inhibitors.\u003c\/p\u003e \u003cp\u003ePostganglionic Neuron Inhibitors Highlights.\u003c\/p\u003e \u003cp\u003eBeta-Blockers—General.\u003c\/p\u003e \u003cp\u003eSide Effects and Contraindications of Beta-Blockers.\u003c\/p\u003e \u003cp\u003eDrug Interactions with Beta-Blockers.\u003c\/p\u003e \u003cp\u003eBeta-Blockers Highlights.\u003c\/p\u003e \u003cp\u003eDirect Vasodilators.\u003c\/p\u003e \u003cp\u003eDirect Vasodilators Highlights.\u003c\/p\u003e \u003cp\u003eAlpha1-Blockers.\u003c\/p\u003e \u003cp\u003eAlpha1-Blockers: Highlights.\u003c\/p\u003e \u003cp\u003eAngiotensin-Converting Enzyme (ACE) Inhibitors.\u003c\/p\u003e \u003cp\u003eRenin-Angiotensin System (RAAS).\u003c\/p\u003e \u003cp\u003eACE Inhibitors: Highlights.\u003c\/p\u003e \u003cp\u003eNon Hypertensive Treatment Effects of ACEIs.\u003c\/p\u003e \u003cp\u003eCalcium Channel Blockers.\u003c\/p\u003e \u003cp\u003eCalcium Channel Blockers: Highlights.\u003c\/p\u003e \u003cp\u003eTreatment: Non Hypertensive Effects of CCBs.\u003c\/p\u003e \u003cp\u003eAngiotensin II Receptor Blockers (ARBs).\u003c\/p\u003e \u003cp\u003eAng-II Receptor Blockers (ARBs): Highlights.\u003c\/p\u003e \u003cp\u003eNon Hypertensive Treatment effects of ARB’s.\u003c\/p\u003e \u003cp\u003eRenin Inhibitors.\u003c\/p\u003e \u003cp\u003eSerum Aldosterone Receptor Antagonists (SARA’s).\u003c\/p\u003e \u003cp\u003eCombination of Anti-hypertensive Drug with Statin ( Amlodipine with Atorvastatin).\u003c\/p\u003e \u003cp\u003e\u003cb\u003eArterial Compliance: Structure\/Function: Treatment.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSelected Combination Antihypertensive Drugs.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eHypertension Drug Selection: Summary.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eNew Antihypertensive Drug Classes.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSubset Selection of Antihypertensive Therapy.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eConclusions 383.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eReferences 385.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eIndex 400.\u003c\/b\u003e\u003c\/p\u003e\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eSubject Areas: Medicine: general issues [\u003ca title=\"See our other books on Medicine: general issues\" href=\"https:\/\/freshlyprintedbooks.co.uk\/search?q=%22Medicine:%20general%20issues%20%5BMB%5D%22\"\u003eMB\u003c\/a\u003e]\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\u003c\/font\u003e","brand":"Wiley-Blackwell","offers":[{"title":"Brand New","offer_id":52502967943448,"sku":"9781405182508","price":67.79,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0730\/2037\/5320\/files\/9781405182508.jpg?v=1786321597","url":"https:\/\/freshlyprintedbooks.co.uk\/products\/handbook-of-hypertension-paperback-softback-9781405182508","provider":"Freshly Printed Books","version":"1.0","type":"link"}